Biotech

All Articles

Ascendis' dwarfism drug favorites in stage 3, threatens BioMarin

.Ascendis Pharma has become a prospective danger to BioMarin's Voxzogo, disclosing phase 3 developme...

Despite ph. 3 skip, Alkeus observes pathway ahead of time for eye illness property

.Though Alkeus Pharmaceuticals' oral eye health condition possession failed to substantially lower g...

Kairos goes public with $6M IPO to fund tests of cancer drug

.With a triad of biotechs striking the Nasdaq on Friday, it was very easy to skip a smaller-scale so...

Vaccine and also Keytruda combo reliable in squamous tissue carcinoma

.Invulnerable gate preventions are the superheroes of cancer cells treatment. Medicines like Bristol...

Cue Biopharma queues up J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of notable management hirings, shootings as wel...

Regeneron's Opdualag rival shows 57% reaction fee

.Regeneron is back along with long-term consequence for its own LAG-3 inhibitor and PD-1 prevention ...

AstraZeneca posts information on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually shared a very early consider the efficiency of its own in-house antibody-d...

iTeos- GSK's TIGIT celebrity reveals significant renovation

.After revealing a stage 3 launch based on beneficial midstage outcomes, iTeos as well as GSK are ac...

More joint FDA can speed up unusual condition R&ampD: file

.The FDA ought to be a lot more open as well as collective to let loose a rise in approvals of rare ...

Zenas, MBX, Bicara head to Nasdaq in hot time for biotech IPOs

.It's an extraordinarily active Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bi...